Public Employees Retirement System of Ohio Buys Shares of 681,832 Abbott Laboratories $ABT

Public Employees Retirement System of Ohio bought a new position in Abbott Laboratories (NYSE:ABT) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 681,832 shares of the healthcare product maker’s stock, valued at approximately $61,869,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories in the 4th quarter valued at approximately $25,000. Cornerstone Financial Management LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter valued at $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories during the 4th quarter worth $26,000. Finally, Abound Financial LLC bought a new position in Abbott Laboratories in the fourth quarter valued at about $26,000. 75.18% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on ABT. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. BTIG Research raised their price objective on shares of Abbott Laboratories from $131.00 to $134.00 and gave the company a “buy” rating in a report on Friday, July 17th. TD Cowen boosted their target price on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Bank of America decreased their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Finally, JPMorgan Chase & Co. raised their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Price Performance

Shares of ABT opened at $110.52 on Thursday. The business has a 50-day moving average of $103.83 and a 200-day moving average of $100.09. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company has a market capitalization of $191.24 billion, a price-to-earnings ratio of 35.77, a price-to-earnings-growth ratio of 2.02 and a beta of 0.59. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter in the prior year, the firm posted $1.26 EPS. The company’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s payout ratio is presently 81.55%.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott outperformed the market during the latest trading session, supported by continued investor interest in the diversified healthcare-products maker. Its shares are trading above both the 50-day and 200-day moving averages, indicating favorable near-term momentum. Abbott Exceeds Market Returns: Some Facts to Consider
• Positive Sentiment: Abbott’s latest reported quarter showed solid fundamentals: adjusted earnings exceeded consensus estimates, revenue surpassed expectations, and sales increased 13% year over year. Management’s 2026 earnings guidance remains consistent with analyst expectations, helping support the investment case.
• Neutral Sentiment: Industry research projects continued growth in cardiovascular ultrasound systems through 2030, driven by portable devices, artificial intelligence, 3D/Doppler imaging and remote diagnostics. The opportunity is broadly relevant to Abbott’s cardiovascular-device business, although the report primarily highlights GE HealthCare, Philips and Siemens Healthineers rather than announcing a specific Abbott development. Cardiovascular Ultrasound Systems Market Outlook
• Neutral Sentiment: Recent commentary notes that Abbott has lagged the healthcare sector over the past year, but analysts remain broadly optimistic about its long-term prospects. This creates a mixed backdrop: valuation and relative performance could restrain gains, while analyst confidence and business diversification provide support. Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector?

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.